Immunohistochemistry or IHC
Update on Diagnosing and Reporting Malignant Pleural Mesothelioma
Acta Medica Academica 2021 April [Link] Ivana Savic, Jeffrey Myers Abstract In this review, we summarize current approaches to diagnosis of malignant pleural mesothelioma, focusing on the distinction from benign mesothelial proliferations and other malignant tumors. Current recommendations for reporting histological sub-type and tumor grade are also reviewed. Particular emphasis is placed on immunohistochemical and…
Read MoreDiagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology
Cytopathology 2021 May 25 [Link] Amber Louw, Y C Gary Lee, Nathan Acott, Jenette Creaney, Chris van Vliet, Siaw Ming Chai Abstract Objective: To assess the utility of BRCA1-associated protein 1 (BAP1) immunohistochemistry (IHC) for the diagnosis of malignant pleural mesothelioma (MPM) in fluid samples with atypical cytology. Methods: Pleural fluid samples with an atypical…
Read MoreMetastasis-associated gene 1 (MTA1) enhances cisplatin resistance of malignant pleural mesothelioma by ATR-Chk1-mediated DNA repair
Annals of Translational Medicine 2021 April [Link] Caihua Xu, Yufeng Hu, Bin Chen, Dapeng Li, Rongrui Liang, Meng Shen, Mengyao Wu, Min Tao Abstract Background: Malignant pleural mesothelioma (MPM) chemoresistance remains a challenge to oncologists. In our previous study, we demonstrated that the aberrant expression of metastasis-associated gene 1 (MTA1) is associated with carcinogenesis and…
Read MoreHigh tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma
The Journal of Pathology. Clinical Research 2021 May 6 [Link] Hely Ollila, Juuso Paajanen, Henrik Wolff, Ilkka Ilonen, Eva Sutinen, Katja Välimäki, Arne Östman, Sisko Anttila, Eeva Kettunen, Jari Räsänen, Olli Kallioniemi, Marjukka Myllärniemi, Mikko I Mäyränpää, Teijo Pellinen Abstract Malignant pleural mesothelioma (MPM) has a rich stromal component containing mesenchymal fibroblasts. However, the properties…
Read MoreSarcomatoid Mesothelioma: A Clinicopathological and Immunohistochemical Study of 64 Cases
International Journal of Surgical Pathology 2021 May 3 [Link] Diana M Oramas, Michael Zaleski, Cesar A Moran Abstract Sixty-four cases of sarcomatoid pleural mesothelioma represent the basis of this study. The patients are 51 men and 13 women between the ages of 42 and 79 years, who presented with symptoms of chest pain, cough, and…
Read MoreMesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors
Biomedicines 2021 April 7 [Link] Sören Weidemann, Pauline Gagelmann, Natalia Gorbokon, Maximilian Lennartz, Anne Menz, Andreas M Luebke, Martina Kluth, Claudia Hube-Magg, Niclas C Blessin, Christoph Fraune, Katharina Möller, Christian Bernreuther, Patrick Lebok, Till S Clauditz, Frank Jacobsen, Jakob R Izbicki, Kristina Jansen, Guido Sauter, Ria Uhlig, Waldemar Wilczak, Stefan Steurer, Sarah Minner, Eike Burandt,…
Read MoreL1CAM expression in cystic mesothelial lesions: a comparison with adenomatoid tumors, well-differentiated papillary mesothelial tumors and malignant mesotheliomas
Histopathology 2021 April 13 [Link] Georgia Karpathiou, Francois Casteillo, Maroa Dridi, Alexandra Papoudou-Bai, Jean Marc Dumollard, Michel Peoc’h Abstract Malignant mesothelioma (MM), the primary cancer of the mesothelium, is characterized by dismal prognosis. However, there are other forms of primary mesothelial tumors, which are benign, the adenomatoid tumors (AT) and the well-differentiated papillary mesothelial tumor…
Read MoreMalignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression
Clinical and Translational Oncology 2021 April 10 [Link] L Gutierrez-Sainz, P Cruz, S Martinez-Recio, O Higuera, M I Esteban-Rodriguez, F Arias-Lotto, R A Gonzalez, J De Castro-Carpeño Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, with a poor prognosis. MPM needs to find prognostic factors of survival. We provided the management…
Read MoreMalignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression
Clinical and Translational Oncology 2021 April 10 [Link] L Gutierrez-Sainz, P Cruz, S Martinez-Recio, O Higuera, M I Esteban-Rodriguez, F Arias-Lotto, R A Gonzalez, J De Castro-Carpeño Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, with a poor prognosis. MPM needs to find prognostic factors of survival. We provided the management…
Read MoreP14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment
Frontiers in Oncology 2021 March 22 [Link] Federica Pezzuto, Francesca Lunardi, Luca Vedovelli, Francesco Fortarezza, Loredana Urso, Federica Grosso, Giovanni Luca Ceresoli, Izidor Kern, Gregor Vlacic, Eleonora Faccioli, Marco Schiavon, Dario Gregori, Federico Rea, Giulia Pasello, Fiorella Calabrese Abstract Introduction: The CDKN2A gene plays a central role in the pathogenesis of malignant pleural mesothelioma (MPM).…
Read More